Clinical trials: Cabozantinib
Bone Metastases, Castrate-resistant Prostate Cancer
Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostate Cancer
This study is being done to help researchers understand more about prostate cancer that has spread to the bones by using the newest magnetic resonance imaging (MRI) techniques and to better understand the effect of an…
- Conditions
- Bone Metastases, Castrate-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01599793
- Testing
- cabozantinib, laboratory biomarker analysis, magnetic resonance imaging
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Chicago
Metastatic Well Differentiated Neuroendocrine Neoplasm, Neuroendocrine Tumors
A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
- Trial name
- LOLA (NCT04427787)
- Testing
- Cabozantinib, Lanreotide
- Where
- Italy
- Volunteers
- 69 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Carcinoma, Non-Small-Cell Lung
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab given in combination with cabozantinib compared with docetaxel monotherapy in patients…
- Trial name
- CONTACT-01 (NCT04471428)
- Testing
- Cabozantinib, Atezolizumab, Docetaxel
- Where
- 92 sites in United States, Australia and 13 more
- Volunteers
- 366 people
- Sponsor
- Hoffmann-La Roche
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Metastatic Hormone Refractory Prostate Cancer
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
The goal of this study is to determine the recommended phase 2 dose of the multi-drug combination of abiraterone, cabozantinib, and nivolumab in conjunction with ongoing androgen deprivation therapy in previously untreated…
- Trial name
- NCT04477512
- Testing
- Cabozantinib, Nivolumab, Abiraterone acetate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
The purpose of the study is to evaluate the progression-free survival (PFS) of casdatifan versus placebo when each is given in combination with cabozantinib for patients who received anti-PD-1 or anti-PD-L1 therapy as part of the…
- Trial name
- NCT07011719
- Testing
- Casdatifan, Cabozantinib
- Where
- 191 sites in United States, Argentina and 15 more
- Volunteers
- 720 people
- Sponsor
- Arcus Biosciences, Inc.
Metastatic Renal Cell Carcinoma (mRCC)
International Multicentric Study ARON-1
The ARON-1 Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of immuno-combinations in patients with metastatic RCC.
- Trial name
- NCT05287464
- Testing
- pembrolizumab plus axitinib
- Where
- Italy
- Volunteers
- 1,220 people
- Sponsor
- Hospital of Macerata
Urothelial Carcinoma
Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.
In this Phase II study we investigate the benefit of cabozantinib treatment for patients with locally advanced or metastasized urothelial cell carcinoma who have been pre-treated with checkpoint inhibitors only (cohort 1) or who…
- Trial name
- CabUC (NCT04066595)
- Testing
- Cabozantinib
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Johannes Gutenberg University Mainz
Lymphoma, Cancer
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
The purpose of this study is to determine the best and safest dose of XL184 administered orally. XL184 is a new chemical entity that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.
- Conditions
- Lymphoma, Cancer, Thyroid Carcinoma
- Trial name
- NCT00215605
- Testing
- XL184
- Where
- 5 sites in United States
- Volunteers
- 85 people
- Sponsor
- Exelixis
Kidney Neoplasm
Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer
The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients…
- Trial name
- IREKI (NCT04823923)
- Testing
- blood sampling for ITK dosage
- Where
- 5 sites in France
- Volunteers
- 60 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Refractory Colorectal Adenocarcinoma
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
This is a phase II non-randomised and non-comparative study, in pretreated mCRC patients, progressed after at least 2 lines of prior chemotherapy for metastatic disease.
- Trial name
- ABACO (NCT06171854)
- Testing
- Cabozantinib
- Where
- Italy
- Volunteers
- 33 people
- Sponsor
- University of Campania Luigi Vanvitelli
Gastric Cancer, Esophageal Adenocarcinoma
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
The investigators propose to evaluate the safety of drug combinations in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies.
- Conditions
- Gastric Cancer, Esophageal Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- CAMILLA (NCT03539822)
- Testing
- Cabozantinib, Durvalumab, Tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 117 people
- Sponsor
- Anwaar Saeed
Advanced Renal Cell Carcinoma
A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma
The purpose of this study is to evaluate the efficacy of cabozantinib measured by Independent Radiology Committee (IRC)-assessed objective response rate (ORR) in Japanese participants with advanced renal cell carcinoma (RCC) that…
- Trial name
- NCT03339219
- Testing
- Cabozantinib
- Where
- 19 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Takeda
Metastatic Kidney Cancer, Metastatic Kidney Carcinoma
CARE1 Pragmatic Clinical Trial
Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI)…
- Trial name
- CARE1 (NCT06364631)
- Testing
- Nivolumab, Ipilimumab, Pembrolizumab
- Where
- 46 sites in Austria, Czechia and 2 more
- Volunteers
- 1,250 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Renal Cell Carcinoma Treated With Cabozantinib
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
- Trial name
- Cabo App (NCT03867045)
- Testing
- Usability of an electronic symptom management application
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Neuroendocrine Tumor, Anaplastic Thyroid Cancer
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
CABATEN is a multicohort phase II study of cabozantinib plus atezolizumab in advanced and progressive tumors from endocrine system.
- Conditions
- Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma, Pheochromocytoma
- Trial name
- CABATEN (NCT04400474)
- Testing
- Cabozantinib 40 mg
- Where
- 15 sites in Spain
- Volunteers
- 93 people
- Sponsor
- Grupo Espanol de Tumores Neuroendocrinos
Neuroblastoma, Sarcoma
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon…
- Trial name
- NCT05135975
- Testing
- Cabozantinib
- Where
- 6 sites in United States
- Volunteers
- 86 people
- Sponsor
- Nationwide Children's Hospital
Advanced Hepatocellular Carcinoma
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic…
- Trial name
- NCT05797805
- Testing
- Tegavivint, Lenvatinib, Cabozantinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Iterion Therapeutics
Advanced Metastatic Melanoma
Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma
The study aims to evaluate the safety and preliminary efficacy of the combination of cabozantinib and pembrolizumab in advanced melanoma
- Trial name
- NCT03957551
- Testing
- Cabozantinib, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- John Rieth
Solid Tumors, Cancer
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese…
- Conditions
- Solid Tumors, Cancer, NSCLC
- Trial name
- NCT01553656
- Testing
- cabozantinib capsules, cabozantinib tablets
- Where
- 2 sites in Japan
- Volunteers
- 85 people
- Sponsor
- Exelixis